Mr. Ian Robertson of Kingsdale Advisors reports

CANNIMED THERAPEUTICS POSTPONES SPECIAL SHAREHOLDERS' MEETING

CanniMed Therapeutics Inc. has determined to postpone the special shareholders meeting, originally scheduled for Jan. 23, 2018, to Thursday, Jan. 25, at 10 a.m. EST. The cut-off time for the deposit of proxies will be at 10 a.m. EST on Tuesday, Jan. 23, 2018, being 48 hours prior to the time of the meeting. Newstrike Resources Ltd. has consented to such postponement. The meeting will be held at the offices of Borden Ladner Gervais LLP, Bay Adelaide Centre East Tower, 22 Adelaide St. West, Toronto, Ont., M5H 4E3, 34th floor.

CanniMed has determined to postpone the meeting to allow discussions regarding a possible transaction with Aurora Cannabis Inc., as permitted under the terms of the arrangement agreement between CanniMed and Newstike dated Nov. 17, 2017. There is no certainty that any such discussion will result in an agreement among the parties in respect of a transaction or in any change to the terms of Aurora's offer, dated Nov. 24, 2017 (as amended).

CanniMed and Aurora have each agreed to a standstill until Jan. 21, 2018, at 11:59 p.m. EST, and until such time, and in connection therewith: (i) Neither CanniMed nor Aurora will solicit any proxies of CanniMed shareholders; (ii) Aurora will not, directly or indirectly, acquire control or direction over any additional shares of CanniMed; (iii) Neither CanniMed nor Aurora will make any announcement or public statements in respect of a potential transaction nor will Aurora make or publicly announce any changes to its offer dated Nov. 24, 2017 (as amended), unless mutually agreed; and (iv) Neither CanniMed nor Aurora will solicit an alternative transaction or enter into any discussions or negotiations with respect to an alternative transaction during the standstill period.

The meeting has been called to consider an ordinary resolution of the shareholders of CanniMed approving the issuance or reservation for issuance of such number of common shares of CanniMed as may be required pursuant to the plan of arrangement relating to the acquisition of Newstrike, all as more particulars, described in the management information circular of CanniMed dated Dec. 8, 2017, available on SEDAR. The meeting will proceed on Jan. 25, 2018, unless adjourned or postponed further.

Advisers

Kingsdale Advisors is acting as strategic shareholder and communications adviser. AltaCorp Capital Inc. is acting as financial adviser to the board and Borden Ladner Gervais LLP is acting as legal adviser to the board. Cormark Securities Inc. is acting as financial adviser to the special committee and Stikeman Elliott LLP is acting as legal adviser to the special committee.

About CanniMed Therapeutics Inc.

CanniMed is a Canadian-based, international plant biopharmaceutical company and a leader in the Canadian medical cannabis industry, with 17 years of pharmaceutical cannabis cultivation experience, state-of-the-art, GMP-(good manufacturing practices)-compliant production process, and world-class research and development platforms with a wide range of pharmaceutical-grade cannabis products. In addition, the company has an active plant biotechnology research and product development program focused on the production of plant-based materials for pharmaceutical, agricultural and environmental applications.

CanniMed, through its subsidiaries, was the first producer to be licensed under the Marijuana for Medical Purposes Regulations, the predecessor to the current Access to Cannabis for Medical Purposes Regulations. It was the sole supplier to Health Canada under the former medical cannabis system for 13 years, and has been producing safe and consistent medical cannabis for thousands of Canadian patients, with no incident of product diversion or recalls.